Search tips
Search criteria 


Logo of ploscurrentsLink to Publisher's site
Version 1. PLoS Curr. 2010 September 5; 2: RRN1165.
PMCID: PMC2928332

Genetic content of Influenza H3N2 vaccine seeds


Influenza vaccine seeds produced in chicken eggs are selected through HA and NA surface glycoproteins antigenicity, as well as through high replicative ability. Here we characterize the genetic content of recently used thirteen H3N2 influenza vaccine seeds. Interestingly, sequence analysis of the vaccine seeds shows reassortment events leading to PR8:H3N2 segment constellations, ranging from the 6:2 to 2:6 constellations. This study shows that the H3N2 PB1 is the most frequent internal segment incorporated in the tested vaccines seeds.


Influenza A viruses are members of the Orthomyxoviridae family [1] . Their genomes consist of eightsingle-stranded RNA segments of negative polarity [2] . The influenza genome evolves in two ways: antigenic shift and antigenic drift. Antigenic shift involves a genetic rearrangement of segments of different viral origins during a co-infection event and might result in the emergence of pandemic virus [3] . Antigenic drifts are causedby frequent mutations during the replication step introduced by the viral polymerase complex: the viruses can be antigenically different and cause epidemics [4].

Vaccination is the cornerstone of influenza prevention, and constant surveillance is necessary as a result of changes in the virus driven by antigenic drift. Vaccines are protective if the strains composing them antigenically match circulating strains. The World health organization (WHO) coordinates influenza surveillance programs and twice a year, reference strains included in vaccines of the North and South hemispheres are sent to manufacturers. Influenza vaccines are usually trivalent, including representative surface antigens of the three major subtypes circulating in humans: A(H1N1), A(H3N2) and B. Epidemic vaccines are prepared almost entirely from viruses grown in the allantoic cavity of 9- to 11-days-old embryonated chicken eggs [5] . Each type A vaccine seed is produced by co-infection of chicken eggs with one selected reference strain (A(H1N1) or A(H3N2)) and with the acceptor strain, A/Puerto Rico/8/1934 (H1N1) (PR8), an attenuated human strain with high growth performance. Vaccine seeds are selected on two criteria: high growth properties and presence of reference strain major antigens, i.e. hemagglutinin (HA) and neuraminidase (NA) proteins. However, vaccine production in chicken eggs has several disadvantages given that the method is time comsuming and cumbersome. In recent years, several manufacturers have explored alternative approaches using accredited mammalian cell lines, e.g. African Green monkey kidney (Vero) cells [6] , Madin-Darby canine kidney (MDCK) cells [7] or PER.C6 cells [8] . In the future, plasmid-based reverse genetics could be applied for the production of viruses from selected plasmids (for reviews see [9] and [10] ).

In this study, we analyzed the segment constellation of thirteen H3N2-based vaccine seeds in order to define their exact genetic content. Our results reveal that H3N2 internal segments were present in the vaccine seeds more han expected.

Methods: Vaccine seed sequencing

Vaccine seeds from manufacturers were kindly provided by the Centre National de Référence Grippe France Sud. Thirteen H3N2 vaccine seeds were analyzed (Table 1). Viral RNAs (vRNA) were extracted directly from virus-containing allantoic fluid (150 µl) using RNA isolation kit (Macherey Nagel) according to the manufacturer’s instructions. vRNAs were eluted in 50 µl of nuclease-free water. A reverse-transcription step was performed with an Uni12 primer (5’-AGCGAAAGCAGG-3’) [11] and 10 µl of extracted vRNA, in a total volume of 20 µl for 5 min at 70°C, followed by 1 h at 42°C and 5 min at 65°C. Fragments of each of the eight viral cDNA were generated from 2 µl of cDNA using GoTaq DNA polymerase (Promega) and the following PCR cycling conditions: 2 min at 94°C, followed by 39 cycles of amplification (30 sec at 94°C, 1 min at 57 or 58°C, and 2 min at 72°C) and a final extension step of 3 min at 72°C. Primer sequences are available on request. All PCR products were verified by agarose gel electrophoresis and purified using NucleoSpin Extract II (Macherey Nagel). After purification, sequencing was performed by Eurofins MWG Operon or GATC Biotech.

The sequences of the internal segments of vaccine seeds were compared with the corresponding PR8 or H3N2 reference strain sequences as available in Influenza Sequence Database [12]. The nucleotide sequences obtained in this study were available from GenBank under accession numbers CY045983 to CY046060 [13]

Results: Sequence analysis of vaccine seeds

Thirteen of the manufacturer vaccine seeds used between the 1996-1997 and 2007-2008 seasons were sequenced to detail their gene constellation (Table 1). The sequences of glycoproteins-encoding segments were not analyzed, since the presence of H3N2 antigens (HA and NA) in these seeds was a selection criteria. The sequences of the internal segments (PB1, PB2, PA, NP, M and NS) of vaccine seeds were compared with the corresponding PR8 or H3N2 reference strain sequences whenever possible, and a nucleotide blast analysis was performed [12]

figure tab1

Table 1. Gene constellation in vaccine seeds. Viral RNAs of thirteen H3N2-based vaccine seeds were isolated directly from virus-containing allantoic fluid. After a RT step, specific segment PCRs were performed. All PCR products were purified and sequenced to determine the viral signature, i.e. PR8 or reference H3N2 strains. While vaccine seed selection is based on the presence of reference strains antigens, i.e. HA and NA, analysis of the two glycoprotein-encoding segments was not performed.

Coinfection byPR8 and the virus strains: A/Panama/2007/99, A/Wyoming/3/2003, A/Wisconsin/67/2005 and A/Brisbane/10/2007, generated two different reassortant viruses. Four vaccine seeds presented a 6:2 segment constellation (IVR108, NYMC X-147B, NYMC X-161B and IVR147 A). The nine remaining strains were a mosaic of internal PR8/H3N2 segments, ranging from one to four H3N2 segments completed by PR8 ones. No vaccine seeds, among the thirteen tested, contained more than four H3N2 internal segments.  One internal segment from H3N2 virus (NP or PB1), i.e. 5:3 reassortant, was incorporated in three vaccines seeds, RESVIR9, RESVIR17A and IVR147 B. Four vaccine seeds corresponded to 4:4 reassortant viruses (Table 2). They had incorporated two H3N2 internal segments: PB1 and NP (RESVIR17B and NYMC X-147A), PB2 and NP (IVR135) or PB1 and M segments (X-157). Two vaccine seeds presented the complete polymerase complex from H3N2 (the 3:5 reassortant IVR139 and the 2:6 reassortant NYMC X-161). The H3N2 PA segment was always incorporated with both H3N2 PB2 and PB1 segment. These encoded proteins for a homologous polymerase complex.

The majority of segments originated from PR8, but internal segments of reference H3N2 viruses were also incorporated (Figure 1). Overall, 54 % of the vaccine seeds (7 out of 13) contained   the H3N2 PB1 segment, which was thus the  H3N2 segment with highest incorporation rate. H3N2 NP segment was present in 4 out of 13 (31%) of the vaccine seeds. H3N2 PB2 and PA segments represented respectively 23% and 15% of the total segments. Finally, H3N2 M and NS segments were detected once in the thirteen seeds analyzed (8%).

figure fig1

Figure 1. Distribution of each segment according to their viral origin PR8 or H3N2 reference strain in the thirteen analyzed vaccine seeds.

Aside from segment determination, reassortant viruses presented five different PR8:H3N2 gene constellations (Table 2). All internal H3N2 segments were incorporated at least once in vaccine seeds. 30 % of the tested vaccine seeds (4 out of 13) contained a 6:2 gene composition. One quarter of vaccine seeds presented a 5:3 constellation. About one-third of analyzed seeds incorporated two H3N2 internal segments, leading to 4:4 reassortants. One seed (IVR139) presented a 3:5 constellation and one another (NYMC X-161) a 2:6 constellation. 

figure tab2

Table 2. Distribution of vaccine seeds according to their genetic composition.


Reassortment events in influenza viruses occur in a non -random way [14] due to associations between putative segments during packaging [15] and functional cooperation of proteins [16] . Influenza H3N2 vaccine seeds produced by co-infection were never entirely determined. In recent years, manufacturers have begun to characterize some of the internal segments, i.e. NP and M segments, to ensure that they contain a PR8 origin. The number of segments corresponding to PR8 segments in the vaccine seed seems to define the pathogenicity [17] and the replicative capacities of the virus. We sequenced thirteen H3N2 vaccine seeds to define their genetic composition. Incorporation of H3N2 internal segment(s) in vaccine seeds has not been reported before in spite of work based on reassortment events between PR8 and H3N2 viruses [14] [18]. Numerous studies considered that influenza vaccine seeds corresponded to 6:2 reassortants, i.e. PR8 genetic background completed with reference strain glycoproteins-encoding segments [[5], [19],[20],[21] ] . We demonstrate here that two thirds of vaccine seeds contained a mosaic of internal segments from the two viral origins, PR8 and H3N2 reference strain. Internal H3N2 segments were not incorporated with the same rate even if all of them have been packaged at least once. H3N2 M segment was encountered only once in analyzed vaccine seeds, despite the association of M proteins with others viral constituents [16],[22],[23] and compatibility degree described between HA and M segments [[24] . However, our results are in agreement with the study of Lubeck et al. showing a preferential incorporation of PR8 M segment in high yields reassortant viruses from co-infection experiments between PR8 and H3N2 viruses in cell lines [14]. Interestingly, the H3N2 PA segment was incorporated only in association with H3N2 PB2 and PB1 segments suggesting a role of PA in the polymerase complex stability [25],[26] or in nuclear transport of the polymerase subunits [27] .

Two vaccine seeds have been produced for four reference strains. The main reason for both of them (A/Wyoming/3/2003 (H3N2) and A/Wisconsin/67/2005 (H3N2)) being an inefficient production of the first reassortant (manufacturer’s data). The difference in the gene constellation could explain differences in replication. In this study, we show that the genetic content of vaccine seeds is a mosaic of parental strains. PB1 segment is the most representative H3N2 segment incorporated in analyzed vaccine seeds. The presence of H3N2 PB1 segment in vaccines as well as in the 2009 H1N1 pandemic influenza virus must provide a selective advantage that needs further investigation. 


Thanks to Sylvaine Faure for technical resources and to Jean-Sébastien Casalegno.

Funding sources

CB was funded by the Ministry of Education and Research, France.

Competing interests

The authors declare that no competing interests exist.


  • Wright, P. F., Neumann, G. & Kawaoka, Y. (2007). Othomyxoviruses. In Fields Virology, 5th edn, pp. 1691–1740. Edited by D. M. Knipe & P. M. Howley. Philadelphia, PA: Lippincott Williams & Wilkins.
  • Ritchey MB, Palese P, Kilbourne ED. RNAs of influenza A, B, and C viruses. J Virol. 1976 May;18(2):738-44. [PMC free article] [PubMed]
  • Smith GJ, Bahl J, Vijaykrishna D, Zhang J, Poon LL, Chen H, Webster RG, Peiris JS, Guan Y. Dating the emergence of pandemic influenza viruses. Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11709-12. Epub 2009 Jul 13. [PubMed]
  • RG Webster and WJ Bean , Evolution and ecology of influenza viruses : interspecies transmission. In: KG Nicholson, RG Webster and AJ Hay, Editors, Textbook of influenza, Blackwell Science Ltd, Oxford (1998), pp. 109–125.
  • Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003 May 1;21(16):1776-9. [PubMed]
  • Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine. 2005 Apr 22;23(22):2943-52. [PubMed]
  • Liu J, Shi X, Schwartz R, Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine. 2009 Oct 30;27(46):6460-3. Epub 2009 Jun 24. [PubMed]
  • Koudstaal W, Hartgroves L, Havenga M, Legastelois I, Ophorst C, Sieuwerts M, Zuijdgeest D, Vogels R, Custers J, de Boer-Luijtze E, de Leeuw O, Cornelissen L, Goudsmit J, Barclay W. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine. 2009 Apr 28;27(19):2588-93. Epub 2009 Feb 20. [PubMed]
  • Neumann G, Kawaoka Y. Reverse genetics systems for the generation of segmented negative-sense RNA viruses entirely from cloned cDNA. Curr Top Microbiol Immunol. 2004;283:43-60. Review. [PubMed]
  • Subbarao K, Katz JM. Influenza vaccines generated by reverse genetics. Curr Top Microbiol Immunol. 2004;283:313-42. Review. [PubMed]
  • Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol. 2001 Dec;146(12):2275-89. [PubMed]
  • The Influenza Sequence Database
  • GenBank
  • Lubeck MD, Palese P, Schulman JL. Nonrandom association of parental genes in influenza A virus recombinants. Virology. 1979 May;95(1):269-74. [PubMed]
  • Marsh GA, Rabadán R, Levine AJ, Palese P. Highly conserved regions of influenza a virus polymerase gene segments are critical for efficient viral RNA packaging. J Virol. 2008 Mar;82(5):2295-304. Epub 2007 Dec 19. [PMC free article] [PubMed]
  • Ito T, Kawaoka Y, Ohira M, Takakuwa H, Yasuda J, Kida H, Otsuki K. Replacement of internal protein genes, with the exception of the matrix, in equine 1 viruses by equine 2 influenza virus genes during evolution in nature. J Vet Med Sci. 1999 Aug;61(8):987-9. [PubMed]
  • Florent G. Gene constellation of live influenza A vaccines. Arch Virol. 1980;64(2):171-3. [PubMed]
  • Voeten JT, Brands R, Palache AM, van Scharrenburg GJ, Rimmelzwaan GF, Osterhaus AD, Claas EC. Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium. Vaccine. 1999 Apr 9;17(15-16):1942-50. [PubMed]
  • Neumann G, Fujii K, Kino Y, Kawaoka Y. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16825-9. Epub 2005 Nov 2. [PubMed]
  • Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol. 2007 Apr;7(4):267-78. Review. [PubMed]
  • Wood JS, Robertson JS. Reference viruses for seasonal and pandemic influenza vaccine preparation. Influenza Other Respi Viruses. 2007 Jan;1(1):5-9. Review. [PubMed]
  • Scholtissek C, Stech J, Krauss S, Webster RG. Cooperation between the hemagglutinin of avian viruses and the matrix protein of human influenza A viruses. J Virol. 2002 Feb;76(4):1781-6. [PMC free article] [PubMed]
  • Li OT, Chan MC, Leung CS, Chan RW, Guan Y, Nicholls JM, Poon LL. Full factorial analysis of mammalian and avian influenza polymerase subunits suggests a role of an efficient polymerase for virus adaptation. PLoS One. 2009 May 21;4(5):e5658. [PMC free article] [PubMed]
  • Li C, Hatta M, Watanabe S, Neumann G, Kawaoka Y. Compatibility among polymerase subunit proteins is a restricting factor in reassortment between equine H7N7 and human H3N2 influenza viruses. J Virol. 2008 Dec;82(23):11880-8. Epub 2008 Sep 24. [PMC free article] [PubMed]
  • Fodor E, Smith M. The PA subunit is required for efficient nuclear accumulation of the PB1 subunit of the influenza A virus RNA polymerase complex. J Virol. 2004 Sep;78(17):9144-53. [PMC free article] [PubMed]
  • Ali A, Avalos RT, Ponimaskin E, Nayak DP. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J Virol. 2000 Sep;74(18):8709-19. [PMC free article] [PubMed]
  • Enami M, Enami K. Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the membrane association of the matrix protein. J Virol. 1996 Oct;70(10):6653-7. [PMC free article] [PubMed]

Articles from PLoS Currents are provided here courtesy of Public Library of Science